Contact Information
Company Information
Company
Apellis Pharmaceuticals
Annual Revenue
781370000.0
Technologies
Salesforce
Mailchimp Mandrill
Sendgrid
Outlook
Microsoft Office 365
Amazon AWS
Route 53
Drupal
ASP.NET
Google Tag Manager
Akamai RUM
Vimeo
New Relic
WordPress.org
Greenhouse.io
Microsoft-IIS
Mobile Friendly
reCAPTCHA
Google Analytics
Google Font API
Gravity Forms
Remote
Keywords
targeted c3 therapies
complement system
hematology
ophthalmology
nephrology
paroxysmal nocturnal hemoglobinuria
geographic atrophy
c3 glomerulopathy
cold agglutinin disease
gene therapy
neurology
amyotrophic lateral sclerosis
biotechnology
life sciences
biotechnology: pharmaceutical preparations
health care
biotechnology research
complement science
c3 therapy
biopharmaceutical
rare diseases
clinical trials
transformative therapies
neurological diseases
medical innovations
healthcare solutions
patient care
corporate responsibility
clinical programs
research & development
drug approval
patient advocacy
life-changing medicines
scientific integrity
innovative treatments
biotech
immunology
compassionate care
community engagement
pipeline development
regulatory compliance
investors relations
stock information
sustainable practices
employee benefits
diversity & inclusion
health economics
biotech careers
corporate governance
environmental stewardship
patient support
healthcare providers
scientific breakthroughs
courageous science
creative solutions
healthcare challenges
retinal diseases
clinical research
drug development
medical technology
pharmaceutical advancements
patient-centric approach
biopharmaceuticals
targeted therapies
empaveli
syfovre
complement inhibitors
autoimmune diseases
patient-centric
patient outcomes
research collaborations
regulatory approvals
market expansion
chronic inflammatory diseases
complement-mediated disorders
global presence
healthcare innovation
therapeutic pipeline
scientific excellence
health
wellness & fitness
hospital & health care
Get Full Contact Details
Subscribe to reveal email addresses and export contacts.
View Plans